CJC-1295 (no DAC)
experimentalAlso known as: Mod GRF 1-29, Modified GRF (1-29)
**Mechanism of Action** CJC-1295 (without DAC) is a synthetic tetrasubstituted analog of growth hormone-releasing hormone (GHRH) comprising amino acids 1–29. Its structural modifications (e.g., substitution at positions 2, 8, 15, and 27) confer resistance to dipeptidyl peptidase IV (DPP-IV) degradation, extending its half-life relative to endogenous GHRH. The peptide binds to pituitary GHRH receptors, stimulating pulsatile growth hormone (GH) secretion in a manner that preserves the natural ultradian rhythm. Unlike the DAC-conjugated variant, this form lacks a drug affinity complex, resulting in a shorter duration of action and a more transient GH pulse. **Key Research Findings** Preclinical and early-phase studies demonstrate that CJC-1295 (no DAC) dose-dependently elevates GH and insulin-like growth factor 1 (IGF-1) levels without abolishing endogenous GH pulsatility. In rodent models, repeated administration increased lean body mass and bone density, with minimal desensitization of the somatotropic axis. Human trials (Phase I/II) reported transient increases in GH and IGF-1 over 2–4 hours post-injection, with mild side effects including flushing and injection-site reactions. No significant alterations in glucose homeostasis or cortisol were observed in short-term studies. However, long-term safety data remain absent. **Clinical Relevance** CJC-1295 (no DAC) is classified as an experimental peptide with no approved therapeutic indications. Its potential applications—such as treating GH deficiency, sarcopenia, or frailty—are speculative and require rigorous clinical validation. Due to its GH-releasing properties, it is subject to regulatory restrictions in many jurisdictions. **For research purposes only — not medical advice.**
Key data
Research & studies
GLP-1 receptor agonists (e.g., semaglutide) are the only class with reproducible randomized evidence for symptomatic knee osteoarthritis improvement, mediated mainly by weight loss.; Collagen-derived injectable preparations showed preliminary postoperative benefits in small, single-center prospective studies.; Regenerative peptides (e.g., BPC-157, thymosin derivatives) and growth hormone secretagogues (e.g., CJC-1295, ipamorelin) remain investigational with uncertain safety and product quality issues.; Clinical use should be limited to approved metabolic agents for indicated conditions and rigorous research protocols, with counseling on antidoping implications.
A refined sample preparation combining ultrafiltration and solid-phase extraction was developed for GHRH and analogs in urine.; The method was fully validated according to WADA guidelines, including selectivity, robustness, and matrix effects.; Achieved LODs of 0.5 ng/mL and LOIs of 0.5-0.75 ng/mL for target peptides in urine.; The method is suitable for both screening and confirmation analyses in anti-doping testing.
Liquid chromatography-high-resolution mass spectrometry (>100,000 FWHM) enables initial testing of prohibited peptides in blood with simplified sample preparation.; Mixed-mode solid-phase extraction allows generic extraction of multiple peptide classes, including insulins, GHRHs, IGFs, and MGFs, from blood.; Blood analysis detects intact peptide hormones at higher concentrations than urine, facilitating detection.; The method fulfills WADA TD2022 MRPL requirements and demonstrated proof of principle with post-administration samples.
Frequently asked questions
What is CJC-1295 (no DAC)?
**Mechanism of Action** CJC-1295 (without DAC) is a synthetic tetrasubstituted analog of growth hormone-releasing hormone (GHRH) comprising amino acids 1–29. Its structural modifications (e.g., substitution at positions 2, 8, 15, and 27) confer resistance to dipeptidyl peptidase IV (DPP-IV) degradation, extending its h
How does CJC-1295 (no DAC) work?
Tetrasubstituted GHRH(1-29) analog with improved enzymatic stability that amplifies pulsatile GH secretion.
What is the research status of CJC-1295 (no DAC)?
CJC-1295 (no DAC) is currently classified as experimental, with 34 research references on record. This is for research purposes only and is not medical advice.
Related peptides
Endogenous cyclic peptide that inhibits GH, insulin, glucagon, and gastric secretion via SSTR1-5 receptors.
Endogenous 28-aa 'hunger hormone' from the stomach; activates GHS-R1a to stimulate GH release and appetite.
First-generation ghrelin receptor agonist hexapeptide that stimulates GH release and strongly increases appetite.
Potent GHRP-family ghrelin receptor agonist with studied cardioprotective effects independent of GH release.
Synthetic hexapeptide ghrelin receptor agonist that potently stimulates GH secretion; also raises appetite, cortisol, and prolactin.
Stabilized GHRH analog approved for HIV-associated lipodystrophy; reduces visceral adipose tissue via GH/IGF-1 axis stimulation.
Build on CJC-1295 (no DAC) data programmatically
Structured peptide data, semantic search, and AI summaries via one API.
Get a free API key